Diagnosis and Management of Denosumab-Induced Hypocalcemia and Hypophosphatemia in the Setting of Metastatic Prostate Cancer

Denosumab, a receptor activator of nuclear factor kappa-Β ligand (RANK-L) monoclonal antibody used in osteoporosis and various malignancies, has been shown to cause hypocalcemia shortly after initiation of treatment. There have been few case reports of electrolyte abnormalities in patients managed w...

Descripción completa

Detalles Bibliográficos
Autores principales: Flood, Michael G, Rowley, Mallory A, Basnet, Alina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812272/
https://www.ncbi.nlm.nih.gov/pubmed/35145817
http://dx.doi.org/10.7759/cureus.20928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812272/
https://www.ncbi.nlm.nih.gov/pubmed/35145817
http://dx.doi.org/10.7759/cureus.20928

Ejemplares similares